Asia Pacific Pharmacogenomics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)

No. of Pages: 170    |    Report Code: TIPRE00028847    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Pharmacogenomics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Pharmacogenomics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific Pharmacogenomics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Increasing demand for personalized medicine
  • 5.1.3 Advancements in genomics and bioinformatics
  • 5.1.4 Rising prevalence of chronic diseases
  • 5.1.5 Growing investments in R&D
  • 5.1.6 Increasing government support for pharmacogenomics research
  • 5.1.7 Rising healthcare expenditure
  • 5.1.8 Growing adoption of pharmacogenomics in clinical practice
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Developing novel therapeutic approaches
  • 5.2.3 Identifying drug targets
  • 5.2.4 Predicting drug response and adverse effects
  • 5.2.5 Optimizing drug dosing
  • 5.2.6 Enhancing clinical trial efficiency
  • 5.2.7 Reducing healthcare costs
  • 5.2.8 Improving patient outcomes
  • 5.2.9 Expanding into emerging markets
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Integration of AI and machine learning
  • 5.3.3 Advancements in next-generation sequencing
  • 5.3.4 Development of pharmacogenomic biomarkers
  • 5.3.5 Expansion of direct-to-consumer genetic testing
  • 5.3.6 Increased collaboration between academia, industry, and healthcare providers
  • 5.3.7 Global regulatory framework for pharmacogenomics
  • 5.3.8 Ethical considerations and privacy concerns
  • 5.3.9 Personalized medicine becoming the standard of care
5.4 Impact of Drivers and Restraints

6. Asia Pacific Pharmacogenomics Market Regional Analysis

6.1 Asia Pacific Pharmacogenomics Market Overview
6.2 Asia Pacific Pharmacogenomics Market Revenue 2019-2028 (US$ Million)
6.3 Asia Pacific Pharmacogenomics Market Forecast Analysis

7. Asia Pacific Pharmacogenomics Market Analysis – by Technology

7.1 PCR
  • 7.1.1 Overview
  • 7.1.2 PCR: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Sequencing
  • 7.2.1 Overview
  • 7.2.2 Sequencing: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Microarray
  • 7.3.1 Overview
  • 7.3.2 Microarray: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Gel Electrophoresis
  • 7.4.1 Overview
  • 7.4.2 Gel Electrophoresis: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Mass Spectrometry
  • 7.5.1 Overview
  • 7.5.2 Mass Spectrometry: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Pharmacogenomics Market Analysis – by Application

8.1 Drug Discovery
  • 8.1.1 Overview
  • 8.1.2 Drug Discovery: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Neurology and Psychiatry
  • 8.3.1 Overview
  • 8.3.2 Neurology and Psychiatry: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Pain Management
  • 8.4.1 Overview
  • 8.4.2 Pain Management: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Cardiovascular Diseases
  • 8.5.1 Overview
  • 8.5.2 Cardiovascular Diseases: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Pharmacogenomics Market Analysis – by End User

9.1 Hospitals and Clinics
  • 9.1.1 Overview
  • 9.1.2 Cardiovascular Diseases: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Biopharmaceutical Companies
  • 9.2.1 Overview
  • 9.2.2 Cardiovascular Diseases: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
9.3 CROs and CDMOs
  • 9.3.1 Overview
  • 9.3.2 Cardiovascular Diseases: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Pharmacogenomics Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific Pharmacogenomics Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Asia Pacific Pharmacogenomics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.1.2 China: Asia Pacific Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.1.3 China: Asia Pacific Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.2 India: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.2.2 India: Asia Pacific Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.2.3 India: Asia Pacific Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.3 Japan: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.3.2 Japan: Asia Pacific Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.3.3 Japan: Asia Pacific Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.4 Australia: Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.4.2 Australia: Asia Pacific Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.4.3 Australia: Asia Pacific Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Pharmacogenomics Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific Pharmacogenomics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Abbott
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 F. HOFFMANN-LA ROCHE LTD.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Oxford Nanopore Technologies
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Illumina, Inc.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 QIAGEN
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Agilent Technologies, Inc.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - A Market

  1. Abbott
  2. F. HOFFMANN-LA ROCHE LTD.
  3. Oxford Nanopore Technologies
  4. THERMO FISHER SCIENTIFIC INC.
  5. Illumina, Inc.
  6. QIAGEN
  7. Agilent Technologies, Inc.
  8. Myriad Genetics, Inc.
asia-pacific-pharmacogenomics-market